Will Summit Therapeutics maintain at least 4 quarters of cash runway through Q2 2026?
Current Prediction
Why This Question Matters
The Stress Scanner assessed funding fragility as STRETCHED. With $713M cash and accelerating burn from multiple expanding programs, the question is whether Summit can reach the PDUFA date without dilutive financing. Additional capital raises would dilute shareholders and signal management concern about approval timeline.
Prediction Distribution
Individual Predictions(9 runs)
Starting from $713M with ~$113M/quarter burn rate gives approximately 6.3 quarters of runway. By Q2 2026 (approximately 2 quarters from now), cash would be roughly $487M. Even with accelerating burn to $130M/quarter, 4 quarters from Q2 would require ~$520M. The math is tight but feasible without additional financing. The question is whether burn accelerates fast enough to erode the buffer.
Even with aggressive burn acceleration to $140M/quarter, by Q2 2026 cash would be approximately $433-487M. At $140M/quarter, 4 quarters = $560M needed — this would be tight. But management stated they have no debt and are cash-conscious. The PIPE raised $5.24B gross. They are unlikely to need additional financing before the PDUFA date.
Three new programs launching in H1 2026 will meaningfully increase burn: ILLUMINE enrollment Q2, GSK trial mid-2026, Revolution Medicines ongoing. If burn jumps to $150M+/quarter, the math gets tight. But even then, the question only asks about 4 quarters of runway at Q2 — which would be approximately $600M at $150M. Starting from ~$487M at Q2, this would resolve NO. Burn acceleration is the key risk.
The math is straightforward: $713M - (2 * ~$120M) = ~$473M at Q2. Four quarters at $120M = $480M needed. It is close but the question resolves based on the 10-Q filing. SBC is non-cash (~$112M/quarter), so actual cash burn is much lower than GAAP expenses. Non-GAAP OpEx of $113M includes some non-cash items. Actual cash burn is likely $90-100M/quarter.
Actual cash consumption is well below the $113M non-GAAP OpEx figure because non-GAAP still includes some non-cash items. Cash from operations is what matters. With $713M and realistic cash burn of $90-100M/quarter, Q2 cash would be $513-533M. Four quarters at $100-110M = $400-440M. Ample room.
The question also resolves NO if Summit announces a new financing round before Q2 2026 10-Q filing. Even if cash is sufficient, management might raise opportunistically. However, with $713M and no debt, a capital raise before Q2 seems unlikely unless the stock price is very high (which could mean positive PFS data).
$713M cash, no debt, 6+ quarters runway. Even with accelerating burn, 4 quarters of runway at Q2 2026 is very likely maintained. Strong starting position.
New programs will increase burn but not enough to breach the 4-quarter threshold by Q2. Cash position is solid. Main risk is an unexpected capital raise, not cash depletion.
The numbers work clearly. $713M with realistic $90-100M quarterly cash burn maintains well above 4 quarters through Q2 2026. High confidence in this outcome.
Resolution Criteria
Resolves YES if Summit's Q2 2026 10-Q shows remaining cash and equivalents sufficient to cover at least 4 additional quarters of operating expenses at the then-current burn rate without additional financing. Resolves NO if cash runway drops below 4 quarters or if Summit announces a new financing round before Q2 2026 10-Q filing.
Resolution Source
Summit Therapeutics Q2 2026 10-Q filing or 8-K financing announcement
Source Trigger
Quarterly cash burn rate accelerating as clinical programs expand
Full multi-lens equity analysis